福州大学最新Nature子刊：新型水凝胶，有效防止致命脑肿瘤的术后复发

Core Viewpoint - Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of only 12-18 months post-diagnosis, and current treatments have limited efficacy in extending patient lifespan [2] Group 1: Research Development - A research team led by Professor Lin Lisen from Fuzhou University and Professor Chen Xiaoyuan from the National University of Singapore published a study in Nature Nanotechnology, introducing a biohybrid chiral hydrogel that enhances postoperative GBM therapy by multi-pronged inhibition of tumor stemness [3][5] - The biohybrid chiral hydrogel is designed for intracavitary implantation after GBM tumor resection, aiming to comprehensively regulate glioblastoma stem cells (GSC) and improve postoperative treatment outcomes [5] Group 2: Mechanism and Efficacy - The hydrogel encapsulates GSC membrane-coated nanoparticles that serve as effective decoys to neutralize chemokines targeting GSC, achieving functional blockade of GSC and hydrogel infiltration [5] - The D-type chiral biohybrid hydrogel, through geometric regulation of mechanical transduction pathways, further diminishes the stemness phenotype of GSC compared to L-type and DL-type counterparts [5] - In three orthotopic GBM models, this multi-faceted GSC stemness inhibition enhances the efficacy of a gold nanoparticle-based hydrogel scaffold sensitized radiotherapy, thereby suppressing postoperative GBM recurrence [5][6]